FIA-Lab ProSIA-Glycan Profiling Sample Pretreatment Module or BRAND NAME EQUIVALENT

This is a combined synopsis/solicitation for commercial services prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6, as supplemented with additional information included in this notice. The incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2021-06.

THIS ANNOUNCEMENT CONSTITUTES THE ONLY SOLICITATION AND A SEPARATE SOLICITATION WILL NOT BE ISSUED.

The request for quotes (RFQ) number for this acquisition is 75F40121Q00058. This will be awarded as a Firm-Fixed Price Purchase Order and 100% Total Small Business Set-Aside. The Government reserves the right to award an order without discussions if the Contracting Officer determines that the initial offer is providing best value and discussions are not necessary.

The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) seeks to procure a FIA-Lab ProSIA-Glycan Profiling Sample Pretreatment Module or BRAND NAME EQUIVALENT for the automation of the Waters GlycoWorks or equivalent derivatization method to support on-line glycan analysis of biotherapeutic protein isolated from crude bioreactor media in real-time and the development of PAT instrumentation for a base-period and three (1) year option periods.